The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer.
Abstract
PURPOSE: While tamoxifen has been shown to alter concentration of many hormones and their binding globulins, there have been conflicting results regarding its effects on thyroid function tests. We sought to clarify these effects by studying subjects in a controlled clinical trial. PATIENTS AND METHODS: We evaluated a subset of postmenopausal women who had participated in a longitudinal, double-blind, randomized, placebo-controlled toxicity study of tamoxifen 10 mg orally, twice daily. There were 14 subjects in both the tamoxifen and placebo groups. Measurement of thyroid-binding globulin (TBG), thyroxine uptake (T-Uptake), thyroxine (T4), and thyroid-stimulating hormone (TSH), and an indirect estimate of the free T4 index (FTI), were made for each subject before and after 3 months of treatment. RESULTS: For T-Uptake, T4, and TBG, there were significant increases in the mean change from baseline to 3 months in the tamoxifen group compared with the placebo group (P = .02, .0001, and .003, respectively), while there were no significant changes in the measured TSH and in the calculated FTI. CONCLUSION: We conclude that tamoxifen therapy in postmenopausal women results in increased TBG, with secondary increases in measured T-Uptake and T4 following. However, TSH and FTI levels are unchanged, and treated women remain eumetabolic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examples of drugs that increase serum TBG from insignificant to significant degrees, include estrogen (201), tamoxifen (202), raloxifene (203), clofibrate (204), opioids (205), mitotane (206), fluorouracil (207), and capecitabine (208).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [202]
In the citing paper
“With the exception of estrogen, these drugs have either not been associated with an altered TSH (202-207), or were shown in case reports only (208).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [202]
Citations
Cites
BERMUDEZ, F., Surks, M. I., & Oppenheimer, J. H. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-1-27 · Cited by 380
Ain, K. B., MORI, Y., & Refetoff, S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-4-689 · Cited by 307
Love, R. R., Newcomb, P. A., Wiebe, D. A., Surawicz, T. S., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.16.1327 · Cited by 292
Self-citationRole of Plasma Proteins in the Binding, Distribution and Metabolism of the Thyroid Hormones
Oppenheimer, J. H. (1968) · New England Journal of Medicine · doi:10.1056/nejm196805232782107 · Cited by 266
Triiodothyronine: Review of recent studies of its physiology and pathophysiology in man
Larsen, P. R. (1972) · Metabolism · doi:10.1016/0026-0495(72)90038-8 · Cited by 137
Variations in Thyroid Hormone Transport Proteins and Their Clinical Implications
Bartalena, L., & ROBBINS, J. J. (1992) · Thyroid · doi:10.1089/thy.1992.2.237 · Cited by 92
THYROID DISEASES AND BREAST CANCER
GOLDMAN, M. B. (1990) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036051 · Cited by 54
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Examples of drugs that increase serum TBG from insignificant to significant degrees, include estrogen (201), tamoxifen (202), raloxifene (203), clofibrate (204), opioids (205), mitotane (206), fluorouracil (207), and capecitabine (208).”
A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism
Colucci, P., Yue, C. S., Ducharme, M., Benvenga, S., Principal Scientist, L. A. C. I., Principal Scientist, L. A. C. I. A. P. C., President and CEO, L. A. C. I., & Professor of Medicine, D. (2010) · European Endocrinology · doi:10.17925/ee.2013.09.01.40 · Cited by 167
Imatinib induces hypothyroidism in patients receiving levothyroxine
DEGROOT, J., ZONNENBERG, B., PLUKKER, J., VANDERGRAAF, W., & LINKS, T. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.010 · Cited by 159
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117
Metadata
- Authors
- Mamby, C. C., Love, R. R., & Lee, K. E.
- Affiliations
- University of Wisconsin–Madison (US)
- ORCID
- Love, R R
- Venue
- Journal of Clinical Oncology
- Published
- 1995-04
- Volume
- 13
- Issue
- 4
- Pages
- 854-857
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1804300286
- Cited by
- 52
- References
- 7
- Citations by year
- 2023: 2 · 2022: 4 · 2021: 1 · 2020: 6 · 2018: 1 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 4 · 2012: 2
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (2r01ca050243-03)
- National Cancer Institute (CA 50243)
- National Center for Research Resources (RR03186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- tamoxifen, thyroid function tests, thyroxine-binding globulin, thyroxine uptake, thyroxine, thyroid-stimulating hormone, free T4 index, postmenopausal women, breast cancer, adjuvant endocrine therapy
- MeSH terms
- Breast Neoplasms, Double-Blind Method, Female, Humans, Longitudinal Studies, Middle Aged, Tamoxifen, Thyroid Function Tests, Thyroid Gland, Thyrotropin, Thyroxine, Thyroxine-Binding Proteins, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
